

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (GH-94)	BUDIGALIMAB
PRONUNCIATION	bue" dij al' i mab
THERAPEUTIC CLAIM	Treatment of metastatic melanoma and non-small cell lung cancer

CHEMICAL NAMES

1. Immunoglobulin G1, anti-(human programmed cell death protein 1), (human-*Mus musculus* monoclonal PR-1648817 γ 1-chain), disulfide with human-*Mus musculus* monoclonal PR-1648817 κ -chain, dimer
2. immunoglobulin G1-kappa, anti-[*Homo sapiens* PDCD1(programmed cell death 1, PD-1, PD1, CD279)], monoclonal antibody;gamma1 heavy chain (1-448) [VH (*Homo sapiens* IGHV1-46*01(76.5%) -(IGHD) -IGHJ6*03 (90.9%)) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03v, G1m3>G1m17, nG1m1 (CH1 R120>K(215) (119-216), hinge (217-231), CH2 L1.3>A (235), L1.2>A (236) (232-341), CH3 E12 (357), M14 (359) (342-446), CHS(447-448)) (119-448)], (221-219')-disulfide with kappa light chain(1'-219') [V-KAPPA (*Mus musculus* IGKV1-117*01(89.0%)/*Homo sapiens* IGKV2-28*01 or IGKV2-29*02 (85.0%) -*Homo sapiens* IGKJ2*01 (100%)) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01, Km3 A45.1 (158), V101 (196) (113'-219')];dimer (227-227":230-230")-bisdisulfide *immunomodulator, antineoplastic*

STRUCTURAL FORMULA

Heavy chain

EIQLVQSGAE	VKKPGSSVKV	SCKASGYTFT	HYGMNWVRQA	PGQGLEWVGW	50
VNTYTGEPTY	ADDFKGRLLTF	TLDTSTSTAY	MELSSLRSED	TAVYYCTREG	100
EGLGFGDWGQ	GTTVTVSSAS	TKGPSVFPLA	PSSKSTSGGT	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTQTYI	200
CNVNHNKPSNT	KVDKKVEPKS	CDKTHTCPPC	PAPEAAGGPS	VFLFPPKPKD	250
TLMISRTPEV	TCVVVDVSHE	DPEVKFNWYV	DGVEVHNAKT	KPREEQYNST	300
YRVVSVLTVL	HQDWLNGKEY	KCKVSNKALP	APIEKTISKA	KGQPREPQVY	350
TLPPSREEMT	KNQVSLTCLV	KGFYPSDIAV	EWESNGQPEN	NYKTTTPVLD	400
SDGSFFLYSK	LTVDKSRWQQ	GNVFSCSVHM	EALHNHYTQK	SLSLSPGK	448

Light chain

DVVMTQSPLS	LPVTPGEPAS	ISCRSSQSIV	HSHGDTYLEW	YLQKPGQSPQ	50'
LLIYKVSNR	SGVPDRFSGS	GSRTDFTLKI	SRVEAEDGVV	YYCFQGSHP	100'
VTFGQGTKLE	IKRTVAAPSV	FIFPPSDEQL	KSGTASVCL	LNNFYPREAK	150'
VQWQVDNALQ	SGNSQESVTE	QDSKDYSTSL	SSTLTLSKAD	YEKHKVYACE	200'
VTHQGLSSPV	TKSFNRGEC				219'

Disulfide bridges

22-96	22"-96"	23'-93'	23'''-93'''	139'-199'	139'''-199'''	145-201	145"-201"
219'-221	219'''-221'''	227-227"	230-230"	262-322	262"-322"	368-426	368"-426"

Glycosylation sites (N)

Asn-298 Asn-298"

MOLECULAR FORMULA

C₆₄₆₈H₉₉₇₄N₁₇₁₄O₂₀₃₆S₄₄ (non-glycosylated)

MOLECULAR WEIGHT

145.7 kDa (non-glycosylated)

TRADEMARK	None as yet
SPONSOR	AbbVie
CODE DESIGNATIONS	ABBV-181; PR-1648817
<u>CAS</u> REGISTRY NUMBER	2098225-93-3
UNII	6VDO4TY300
WHO NUMBER	10908

gbk